Itolizumab, new drug for COVID-19 patients to cost Rs 8,000 per vial

Biotechnology major Biocon on Monday said it will launch biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients at a price of around 8,000 per vial.   The company......

'No preparedness planning, no accountability, no action plan'

'This government did not have any plan for safety stocks of essential medicines.' IMAGE: Doctors attend to a patient suffering from COVID-19 inside the emergency room at the Safdarjung Hospital in......

USFDA's new draft biosimilar rules to benefit Indian biotech cos

The US Food and Drug Administration’s (USFDA)’s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars — lower-priced, near-replicas of complex biologic......

Jt drugs controller waives trial of Biocon drug; arrested

The CBI has arrested Joint Drugs Controller S Eswara Reddy for allegedly receiving a Rs 4 lakh bribe to waive the phase three clinical trial of the Insulin Aspart injection, a product of Biocon......

Bengaluru Traffic Test Corporate Patience

'We do not need short-term measures but long-term ones. Companies seem to have given up on the infrastructure part. Long delays are fuelling more traffic crisis.' IMAGE: Potholes on Bengaluru......

'Ready To Launch 5 products In 18 Months'

'We recently launched Yesintek in the immunology space.' Photograph: Kind courtesy Biocon Biologics Ltd Biocon Biologics Ltd (BBL) reported robust growth in 2024-25 (FY25), driven by rising......